Redeye updates its forecast following Modelon’s Q1 2025 report, where results came roughly in line with expectations on key lines. While macro uncertainty weighs on short-term visibility, strong momentum from Modelon Impact, improving operating loss and a solid cash position continue to support the long-term investment case, which we view as intact.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/